Table 1.
Clinical Trials Involving Chimeric Antigen Receptor or NK Cellular Therapy Actively Recruiting at the Time of this Writing
| ClinicalTrials.gov ID | Description | Intervention | Tumor |
|---|---|---|---|
| NCT02932956 | CAR T cells against Glypican-3-expressing pediatric solid tumors | CAR T cell | Glypican-3-expressing solid tumors (liver) |
| NCT03500991 | CAR T cells against HER2[+] pediatric CNS tumors | CAR T cell | HER2[+] pediatric CNS tumors |
| NCT03638167 | EGFR-specific CAR T cell for CNS tumors | CAR T cell | EGFRvIII gliomas and CNS tumors |
| NCT02315612 | CART T cells against CD22-expressing B cell malignancies | CAR T cell | CD22-expressing B cell malignancies |
| NCT02772198 | CAR T cells against CD19-expressing B cell malignancies (ALL and NHL) | CAR T cell | CD19-expressing malignancy |
| NCT01555892 | CAR T cells against EBV-LMP1, BRAF, and EBNA(+) tumors | CAR T cell | lymphomas and carcinomas |
| NCT02892695 | bridge immunotherapy in unresponsive CD19(+) leukemia lymphoma | CAR-NK+ HSCT | leukemia or lymphoma |
| NCT02573896 | expanded autologous NKs + chimeric IgαGD2 (CH14.18) + lenalidomide | autologous NK | refractory and relapsed neuroblastoma |
| NCT02650648 | expanded autologous NK + humanized IgαGD2 (Hu3F8) | autologous NK | refractory and relapsed neuroblastoma |
| NCT03209869 | expanded autologous NKs + chimeric IgaGD2 (CH14.18) + rIL2 | autologous NK | refractory and relapsed neuroblastoma |
| NCT03420963 | chemotherapy (cyclophosphamide, etoposide, mesna) + NK cells | autologous NK | pediatric solid tumors |
| NCT02100891 | allogeneic HCT + NK cells in pediatric solid tumors: phase II | autologous NK | sarcomas, neuroblastoma, and CNS tumors |
| NCT01823198 | NK cells with HLA-compatible HCT for high-risk myeloid malignancies | autologous NK | AML/myeloproliferative disease |
| NCT01904136 | phase I/II trial of NK cell administration to prevent relapse for high-risk myeloid malignancies undergoing allogeneic stem cell transplantation | autologous NK | AML/myeloproliferative disease |
| NCT02809092 | phase I/II trial of IL-21-expanded NK cells for relapsed/refractory acute myeloid leukemia induction therapy | autologous NK | AML/myeloproliferative disease |
| NCT01898793 | phase 1/2 study of cytokine-induced memory-like NK cells in patients with AML or MDS | autologous NK | AML/myeloproliferative disease |
| NCT01619761 | natural killer cells in allogeneic cord blood transplantation | autologous NK + CB | poor risk hematologic malignancies |
| NCT01326104 | vaccine immunotherapy for recurrent medulloblastoma (phase II DCs) and PNETs (phase I lymphocytes) | tumor-RNA primed DCs or autologous lymphocytes | medulloblastoma and peripheral neuroectodermal tumors (PNETs) |
We searched https://clinicaltrials.gov/ using the terms pediatric cancer + natural killer chimeric antigen receptor or dendritic cell; apologies if we overlooked your study.